The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
=== Cartilage implants === In July 2016, the U.S. approved the use of a synthetic cartilage implant to treat arthritis in the joint of the big toe. The implant is made of saline and a bio-compatible polymer, and is inserted through an incision between the metatarsophalangeal (MTP) joint where natural cartilage has worn away. It is being researched for use in other joints. A separate orthopedic implant consisting of a hydrated, interpenetrating dual polymer network based on polyether urethane (PEU) was given breakthrough device designation from the U.S. Food and Drug Administration in July 2021. In September 2021, researchers used nasal chondrocyte-based engineered cartilage to treat osteoarthritic joints in two patients.
== Dietary intake == As mentioned before, selenomethionine occurs in the human diet. It is one of the main forms of selenium in food along with selenocystine. Selenomethionine is readily available as a dietary supplement. It has been suggested by nutritionists that selenomethionine, as an organic form of selenium, is easier for the human body to absorb than selenite, which is an inorganic form. It was determined in a clinical trial that selenomethionine is absorbed 19% better than selenite.
By 2014, around 20 companies, particularly from emerging markets, were developing biosimilar versions of trastuzumab after Roche/Genentech's patents expired in 2014 in Europe, and in 2019 in the United States. In January 2015, BIOCAD announced the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation. Iran also approved its own version of the monoclonal antibody in January 2016, as AryoTrust, and announced its readiness to export the drug to other countries in the Middle-East and Central Asia when trade sanctions were lifted. In 2016, the investigational biosimilar MYL-1401O showed comparable efficacy and safety to the Herceptin branded trastuzumab. Trastuzumab-dkst (Ogivri, Mylan GmbH) was approved in the United States in December 2017, to "treat people with breast cancer or gastric or gastroesophageal junction adenocarcinoma whose tumors overexpress the HER-2 gene." Ogivri was authorized for medical use in the European Union in December 2018. In November 2017, the European Commission authorized Ontruzant, a biosimilar from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in the European Union. Herzuma was authorized for medical use in the European Union in February 2018. Herzuma, a trastuzumab biosimilar, was approved in the United States in December 2018.
Veterinary pharmacies, sometimes called animal pharmacies, may fall in the category of hospital pharmacy, retail pharmacy or mail-order pharmacy. Veterinary pharmacies stock different varieties and different strengths of medications to fulfill the pharmaceutical needs of animals. Because the needs of animals, as well as the regulations on veterinary medicine, are often very different from those related to people, in some jurisdictions veterinary pharmacy may be kept separate from regular pharmacies.
== In platelets == The alpha granules in blood platelets contain growth factors PDGF, IGF-1, EGF, and TGF-β which begin healing of wounds by attracting and activating macrophages, fibroblasts, and endothelial cells.
Sources: en.wikipedia.org
A bone graft can be created between the two bones using a bone from elsewhere in the person's body (autograft) or using donor bone (allograft) from a bone bank. Bone autograft is generally preferred by surgeons because, as well as eliminating the risks associated with allografts, bone autograft contains native bone-forming cells (osteoblasts), so the graft itself forms new bone (osteoinductive), as well as acting as a matrix or scaffold to new bone growing from the bones being bridged (osteoconductive). The main drawback of bone autograft is the limited supply available for harvest. Bone allograft has the advantage of being available in far larger quantities than autograft; however, during the treatment process the bone goes through following harvest, which usually involves deep-freezing and may also involve demineralization, irradiation and freeze-drying, kills living bone or bone marrow cells. This significantly reduces the immunogenicity (risk of graft rejection) such that no antirejection drugs are needed, and combined with appropriate donor screening practices, these processing and preservation practices can significantly reduce the risk of disease transmission. In spite of all of this processing, cancellous allograft bone retains its osteoconductive properties. Furthermore, certain processing practices have been shown to also retain the acid-stable osteoinductive proteins in cortical bone grafts, so that many bone allografts can be considered both osteoconductive and osteoinductive. A variety of synthetic bone substitutes are commercially available.
The inquiry will have two areas of focus – a review of the "placement and categorisation" of all inmates at Wandsworth, and an investigation of all people in custody currently charged with terror offences. The UK's first EV-only manufacturing plant begins production at Ellesmere Port, Cheshire. The UK experiences a fourth day of temperatures exceeding 30 °C (86 °F), the highest consecutive number on record for the month of September, with hot weather expected to continue until the weekend. 8 September – The first anniversary of the death of Elizabeth II is marked by gun salutes at Hyde Park and the Tower of London, as well as the release of a short message from Charles III along with a previously unreleased portrait of the Queen taken in 1968. 9 September – Following a four-day manhunt, Daniel Khalife is arrested by the Metropolitan Police in Chiswick, London. 10 September The Sunday Times reports that two men have been arrested under the Official Secrets Act, including a researcher in the UK Parliament accused of spying for China. Mo Farah, considered one of the greatest British athletes of all time, takes part in the final race of his career at age 40, finishing fourth in the Great North Run. The Metropolitan Police confirm that Daniel Khalife has been charged with escaping from Wandsworth Prison. He appears before Westminster Magistrates Court the following day, where he is remanded in custody until 29 September. 11 September The GMB Union confirms that the UK's 400 Wilko stores will close by early October after a bid to rescue the retailer fell through.
=== Current research methodologies === Fluorescence two-dimensional differential gel electrophoresis (2-D DIGE) may be used to quantify variation in the 2-D DIGE process and establish statistically valid thresholds for assigning quantitative changes between samples. Comparative proteomic analysis may reveal the role of proteins in complex biological systems, including reproduction. For example, treatment with the insecticide triazophos causes an increase in the content of brown planthopper (Nilaparvata lugens (Stål)) male accessory gland proteins (Acps) that may be transferred to females via mating, causing an increase in fecundity (i.e. birth rate) of females. To identify changes in the types of accessory gland proteins (Acps) and reproductive proteins that mated female planthoppers received from male planthoppers, researchers conducted a comparative proteomic analysis of mated N. lugens females. The results indicated that these proteins participate in the reproductive process of N. lugens adult females and males. Proteome analysis of Arabidopsis peroxisomes has been established as the major unbiased approach for identifying new peroxisomal proteins on a large scale. There are many approaches to characterizing the human proteome, which is estimated to contain between 20,000 and 25,000 non-redundant proteins.
The German Federal Office for Radiation Protection recommends, among other things, mobile phones with a low SAR (Specific Absorption Rate) and the use of headsets or hands-free devices to keep the mobile phone away from the head. There is some discussion that mobile phone radiation may increase the incidence of acoustic neuroma, a benign tumor that arises from the vestibulocochlear nerve. It should therefore be reduced. In everyday life, a mobile phone transmits at maximum power only in exceptional cases. As soon as it is near a cell where maximum power is no longer needed, it is instructed by that cell to reduce its power. Electrosmog or cell phone radiation filters built into cell phones are supposed to protect against radiation. The effect is doubtful from the point of view of electromagnetic environmental compatibility, because the radiation intensity of the cell phone is increased disproportionately in order to obtain the necessary power. The same is true for use in a car without an external antenna, as the necessary radiation can only penetrate through the windows, or in areas with poor network coverage. Since 2004, radio network repeaters have been developed for mobile phone networks (GSM, UMTS, Tetrapol) that can amplify the reception of a mobile phone cell in shaded buildings. This reduces the SAR value of the mobile phone when making calls. The SAR value of a WLAN router is only a tenth of that of a cell phone, although this drops by a further 80% at a distance of just one meter. The router can be set so that it switches off when not in use, for example at night.
=== Mobility === When "Ca. M. multicellularis" is free-swimming, it travels along elongated helical or straight pathways. The consortium has a co-ordinated flagellar rotation, where the organism's body rotates about its axis at the same time and in the same direction as its trajectory. This appears to prevent the formation of a single flagellar bundle while swimming. Under free-swimming conditions, the organism displays spontaneous and temporary shifts back-and-forth along magnetic field lines, known as "ping pong movement" or "escape motility". These rapid directional changes, of nearly 180°, have been interpreted as consistent with a synchronised reversal of flagellar rotation. This movement allows the organism to move more freely under the constraints of a magnetic field.
Sources: en.wikipedia.org
Typically, a broker will market a property on behalf of the seller. Brokers representing buyers or buyers' representatives identify property meeting a set of criteria set out by the buyer. Types of buyers may include an owner-user, private investor, acquisitions, capital investment, or private equity firms. The buyer or its agents will perform an initial assessment of the physical property, location and potential profitability (if for investment) or adequacy of property for its intended use (if for owner-user). If it is determined the prospective investment meets the buyer's criteria, they may signal their intent to move forward with a letter of intent (LOI). Letters of Intent are used to outline the major terms of an offer in order to avoid unnecessary costs of drafting legal documents in the event the parties do not agree to the terms as drafted. Once a Letter of Intent is signed by both parties, a purchase and sale agreement (PSA) is drafted. Not all commercial property transactions utilize a Letter of Intent although it is common. A PSA is a legal agreement between the seller and a single interested buyer which establishes the terms, conditions and timeline of the sale between the buyer and seller. A PSA may be a highly negotiated document with customized terms or may be a standardized contract similar to those used in residential transactions. Once a PSA is executed, the buyer is commonly required to submit an escrow deposit, which may be refundable under certain conditions, to a title company office or held by a brokerage in escrow.
Manufacturing sites were opened in 2011 in the Czech Republic for the industrial, pharmaceutical, chemical, and scientific markets while manufacturing sites for the semiconductor market were opened in South Korea. Most of Edwards' UK manufacturing capacity was moved, with abatement systems remaining in Clevedon, completing plans proposed under BOC in 2005. Edwards was awarded its seventh Queen's Award in 2012, and acquired USA-based Gamma Vacuum in 2013, maintaining the brand until this day. Gamma Vacuum specialises in ion and titanium sublimation pumps, with customers mainly in the scientific industry.
Instrument Landing System (ILS) - A short range radio navigation aid at airports which guides aircraft landing in low visibility conditions. It consists of multiple antennas at the end of each runway that radiate two beams of radio waves along the approach to the runway: the localizer (108 to 111.95 MHz frequency), which provides horizontal guidance, a heading line to keep the aircraft centered on the runway, and the glideslope (329.15 to 335 MHz) for vertical guidance, to keep the aircraft descending at the proper rate for a smooth touchdown at the correct point on the runway. Each aircraft has a receiver instrument and antenna which receives the beams, with an indicator to tell the pilot whether he is on the correct horizontal and vertical approach. The ILS beams are receivable for at least 15 miles, and have a radiated power of 25 watts. ILS systems at airports are being replaced by systems that use satellite navigation. Non-directional beacon (NDB) – Legacy fixed radio beacons used before the VOR system that transmit a simple signal in all directions for aircraft or ships to use for radio direction finding. Aircraft use automatic direction finder (ADF) receivers which use a directional antenna to determine the bearing to the beacon. By taking bearings on two beacons they can determine their position. NDBs use frequencies between 190 and 1750 kHz in the LF and MF bands which propagate beyond the horizon as ground waves or skywaves much farther than VOR beacons. They transmit a callsign consisting of one to 3 Morse code letters as an identifier.
ribosomal DNA (rDNA) A DNA sequence that codes for ribosomal RNA (rRNA). In many eukaryotic genomes, rDNA occupies large, highly conserved regions of multiple chromosomes and is rich in both genes and repeats.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.